Sidekick Health Expands Women’s Health Portfolio with Launch of MENO! App in a New Clinical Study

NEW YORK, March 10, 2025 /PRNewswire/ — Sidekick Health, a leading digital health company, today announced the launch of a clinical study of its latest prescription digital therapeutic (PDT), MENO! App, designed to address the unmet needs of women experiencing menopause. Sidekick is initiating a 12-week clinical study in Germany to further validate the MENO! App’s impact on menopause symptom relief.

Bridging the Gap in Women’s Health

Women’s health has long been an underserved area in medicine. Despite making up half the population, women are underrepresented in clinical research and lack access to tailored, evidence-based care. Menopause, a universal experience, is no exception—one in four women suffer from severe symptoms such as hot flashes, sleep disturbances, and mood changes that significantly impact their quality of life and work. Yet treatment options remain limited and often inaccessible.

“We invest in innovative digital health solutions that address the individual needs of women at various stages of life,” said Prof. Dr. Pia Wülfing, chief clinical officer for Sidekick Health Group and a licensed OB/GYN. “Our focus lies in combining technology with medical expertise to improve healthcare outcomes.”

MENO! App: A New Standard for Menopause Care

MENO! App is a CE-marked digital therapeutic for menopause, offering evidence-based cognitive behavioral therapy (CBT) specifically designed to reduce symptom burden. Unlike traditional menopause treatments that focus solely on Menopause Hormone Therapy (MHT), MENO! App provides a non-hormonal, accessible alternative to help women manage their symptoms holistically. The app integrates behavioral interventions with lifestyle support, empowering users with self-guided tools tailored to their individual health needs.

Advancing Women’s Health Through Research

As part of Sidekick’s commitment to evidence-based care, the company has launched a decentralized, randomized-controlled clinical study in Germany, where Sidekick Health Group already has two PDTs listed in Germany’s regulated nationwide DiGA (Digitale Gesundheitsandwendungen) formulary, PINK! Coach and zanadio. The study will evaluate the effectiveness of MENO! App in a 12-week study that will enroll women aged 40-65 experiencing bothersome menopausal symptoms. Participants will be randomized into two groups—one using the MENO! App and the other receiving standard care. After completion, the control group will also gain access to the app, ensuring all participants benefit from this innovation.